These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 32787082)

  • 21. Research Progress on Small-molecule Inhibitors of Protein Arginine Methyltransferase 5 (PRMT5) for Treating Cancer.
    Guo C; Wu L; Zheng X; Zhao L; Hou X; Wang Z; Han C
    Curr Top Med Chem; 2023; 23(21):2048-2074. PubMed ID: 37438905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer.
    Quiroz RV; Reutershan MH; Schneider SE; Sloman D; Lacey BM; Swalm BM; Yeung CS; Gibeau C; Spellman DS; Rankic DA; Chen D; Witter D; Linn D; Munsell E; Feng G; Xu H; Hughes JME; Lim J; Saurí J; Geddes K; Wan M; Mansueto MS; Follmer NE; Fier PS; Siliphaivanh P; Daublain P; Palte RL; Hayes RP; Lee S; Kawamura S; Silverman S; Sanyal S; Henderson TJ; Ye Y; Gao Y; Nicholson B; Machacek MR
    J Med Chem; 2021 Apr; 64(7):3911-3939. PubMed ID: 33755451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting protein arginine methyltransferase 5 in disease.
    Richters A
    Future Med Chem; 2017 Nov; 9(17):2081-2098. PubMed ID: 29076773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.
    Kryukov GV; Wilson FH; Ruth JR; Paulk J; Tsherniak A; Marlow SE; Vazquez F; Weir BA; Fitzgerald ME; Tanaka M; Bielski CM; Scott JM; Dennis C; Cowley GS; Boehm JS; Root DE; Golub TR; Clish CB; Bradner JE; Hahn WC; Garraway LA
    Science; 2016 Mar; 351(6278):1214-8. PubMed ID: 26912360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel PRMT5-mediated arginine methylations of HSP90A are essential for maintenance of HSP90A function in NDRG2
    Ichikawa T; Shanab O; Nakahata S; Shimosaki S; Manachai N; Ono M; Iha H; Shimoda K; Morishita K
    Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118615. PubMed ID: 31765670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploration of cyanine compounds as selective inhibitors of protein arginine methyltransferases: synthesis and biological evaluation.
    Hu H; Owens EA; Su H; Yan L; Levitz A; Zhao X; Henary M; Zheng YG
    J Med Chem; 2015 Feb; 58(3):1228-43. PubMed ID: 25559100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of Selective, Cell Active Inhibitors of Protein Arginine Methyltransferase 5 through Structure-Based Virtual Screening and Biological Assays.
    Ye F; Zhang W; Ye X; Jin J; Lv Z; Luo C
    J Chem Inf Model; 2018 May; 58(5):1066-1073. PubMed ID: 29672052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
    Han X; Zhao L; Xiang W; Qin C; Miao B; Xu T; Wang M; Yang CY; Chinnaswamy K; Stuckey J; Wang S
    J Med Chem; 2019 Dec; 62(24):11218-11231. PubMed ID: 31804827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protein arginine methyltransferase 5: a potential cancer therapeutic target.
    Yuan Y; Nie H
    Cell Oncol (Dordr); 2021 Feb; 44(1):33-44. PubMed ID: 33469838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.
    Zhang B; Dong S; Zhu R; Hu C; Hou J; Li Y; Zhao Q; Shao X; Bu Q; Li H; Wu Y; Cen X; Zhao Y
    Oncotarget; 2015 Sep; 6(26):22799-811. PubMed ID: 26078354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and characterization of PROTAC degraders specific to protein N-terminal methyltransferase 1.
    Zhou Q; Wu W; Jia K; Qi G; Sun XS; Li P
    Eur J Med Chem; 2022 Dec; 244():114830. PubMed ID: 36228414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of a First-in-Class Inhibitor of the PRMT5-Substrate Adaptor Interaction.
    McKinney DC; McMillan BJ; Ranaghan MJ; Moroco JA; Brousseau M; Mullin-Bernstein Z; O'Keefe M; McCarren P; Mesleh MF; Mulvaney KM; Robinson F; Singh R; Bajrami B; Wagner FF; Hilgraf R; Drysdale MJ; Campbell AJ; Skepner A; Timm DE; Porter D; Kaushik VK; Sellers WR; Ianari A
    J Med Chem; 2021 Aug; 64(15):11148-11168. PubMed ID: 34342224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.
    Mao R; Shao J; Zhu K; Zhang Y; Ding H; Zhang C; Shi Z; Jiang H; Sun D; Duan W; Luo C
    J Med Chem; 2017 Jul; 60(14):6289-6304. PubMed ID: 28650658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance.
    Jensen-Pergakes K; Tatlock J; Maegley KA; McAlpine IJ; McTigue M; Xie T; Dillon CP; Wang Y; Yamazaki S; Spiegel N; Shi M; Nemeth A; Miller N; Hendrickson E; Lam H; Sherrill J; Chung CY; McMillan EA; Bryant SK; Palde P; Braganza J; Brooun A; Deng YL; Goshtasbi V; Kephart SE; Kumpf RA; Liu W; Patman RL; Rui E; Scales S; Tran-Dube M; Wang F; Wythes M; Paul TA
    Mol Cancer Ther; 2022 Jan; 21(1):3-15. PubMed ID: 34737197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with
    Cottrell KM; Briggs KJ; Whittington DA; Jahic H; Ali JA; Davis CB; Gong S; Gotur D; Gu L; McCarren P; Tonini MR; Tsai A; Wilker EW; Yuan H; Zhang M; Zhang W; Huang A; Maxwell JP
    J Med Chem; 2024 Apr; 67(8):6064-6080. PubMed ID: 38595098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of PRMT5 inhibitors with novel scaffold structures through virtual screening and biological evaluations.
    Zhang Q; Zhang L; Jin J; Fan Y; Wang X; Hu H; Ye X; Wang L; Cao C; Ye F
    J Mol Model; 2022 Jun; 28(7):184. PubMed ID: 35680707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
    Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
    J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EPZ015666, a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an antitumour effect in retinoblastoma.
    Liu X; He J; Mao L; Zhang Y; Cui W; Duan S; Jiang A; Gao Y; Sang Y; Huang G
    Exp Eye Res; 2021 Jan; 202():108286. PubMed ID: 33035554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway.
    Ottis P; Palladino C; Thienger P; Britschgi A; Heichinger C; Berrera M; Julien-Laferriere A; Roudnicky F; Kam-Thong T; Bischoff JR; Martoglio B; Pettazzoni P
    ACS Chem Biol; 2019 Oct; 14(10):2215-2223. PubMed ID: 31553577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of protein arginine N-methyltransferase 5 (PRMT5) as a novel interacting protein with the tumor suppressor protein RASSF1A.
    Sakai N; Saito Y; Fujiwara Y; Shiraki T; Imanishi Y; Koshimizu TA; Shibata K
    Biochem Biophys Res Commun; 2015 Nov; 467(4):778-84. PubMed ID: 26482848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.